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Abstract
Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder characterized by the occurrence of schwanno-
mas and meningiomas. Several studies have examined the ability of the NF2 gene product, merlin, to function as a
tumor suppressor in diverse cell types; however, little is known about merlin growth regulation in meningiomas. In
Drosophila, merlin controls cell proliferation and apoptosis by signaling through the Hippo pathway to inhibit the
function of the transcriptional coactivator Yorkie. The Hippo pathway is conserved in mammals. On the basis of
these observations, we developed human meningioma cell lines matched for merlin expression to evaluate merlin
growth regulation and investigate the relationship between NF2 status and Yes-associated protein (YAP), the mam-
malian homolog of Yorkie. NF2 loss in meningioma cells was associated with loss of contact-dependent growth
inhibition, enhanced anchorage-independent growth and increased cell proliferation due to increased S-phase en-
try. In addition, merlin loss in both meningioma cell lines and primary tumors resulted in increased YAP expression
and nuclear localization. Finally, siRNA-mediated reduction of YAP in NF2-deficient meningioma cells rescued the
effects of merlin loss on cell proliferation and S-phase entry. Collectively, these results represent the first demon-
stration that merlin regulates cell growth in human cancer cells by suppressing YAP.
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Introduction
Neurofibromatosis type 2 (NF2) is a cancer predisposition syndrome
phenotypically characterized by the occurrence of multiple nervous
system tumors. The two most common tumors in this inherited syn-
drome are schwannomas and meningiomas [1]. Whereas meningio-
mas from individuals with NF2 exhibit biallelic inactivation of the
NF2 gene, loss of NF2 expression is also detected in as many as
60% of sporadic meningiomas [2]. Similarly, genetically engineered
mice with leptomeningeal NF2 inactivation also develop meningio-
mas [3,4]. These findings strongly implicate the NF2 gene in the
pathogenesis of meningiomas; however, the molecular mechanism
by which NF2 regulates cell growth relevant to meningioma tumor-
igenesis remains unsolved.
Merlin (or schwannomin), the product of the NF2 gene, is a
member of the protein 4.1 family that links the actin cytoskeleton
to plasma membrane proteins [5]. Although few studies have exam-
ined merlin loss in meningioma cells, loss of merlin in fibroblasts and
Schwann cells results in loss of contact-dependent inhibition of pro-
liferation, enhanced growth in soft agar and tumor formation in mice
[6,7]. In these cell types, merlin has been implicated in epidermal
growth factor receptor [8], β1-integrin [9], and CD44 [7] function
as well as Ras [10], Rac1 [11,12], phosphatidylinositol 3-kinase [13],
mitogen-activated protein kinase [14], and signal transducer and ac-
tivator of transcription [15] intracellular signaling. It is not known
whether any of these growth control pathways are deregulated in
NF2-deficient meningioma tumors.
Negative regulation of growth by merlin is conserved inDrosophila,
where it acts upstream of the Hippo signaling pathway to coordinately
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regulate cell proliferation and apoptosis [16,17]. Mutations in mer-
lin or other components of the Hippo pathway such as the serine/
threonine kinases, Hippo and Warts, the adaptor molecule, Salvador,
or Mats, results in activation of the transcriptional coactivator, Yorkie.
Yorkie regulates expression of downstream target genes including
cyclin E andDIAP1 (Drosophila inhibitor of apoptosis protein 1) caus-
ing increased growth, delayed cell cycle exit, inhibition of apoptosis,
and enhanced cell survival [16,17].
Individual components of the Hippo pathway are highly con-
served in mammals, where they also regulate cell proliferation and
apoptosis (Figure 1) [18,19]. Mice and humans have two Warts
orthologs, Lats1 and Lats2. Mice deficient for Lats1 develop soft-
tissue sarcomas and ovarian tumors [20]. The human ortholog of
Salvador, hWW45, is mutated in cancer cell lines [21]. The two
mammalian Hippo homologues, Mst1 and Mst2, promote apoptosis
and regulate cell cycle exit [22]. Vertebrate Mst2 can rescue the lethal-
ity and overgrowth phenotypes of Hippo mutants in Drosophila [23].
Similar to their Drosophila counterparts, human Mst2 phosphory-
lates and activates both Lats1 and Lats2 [24]. The Yes-associated
protein (YAP), the mammalian ortholog of Yorkie, is the primary ef-
fector of the mammalian Hippo pathway. Similar to the function of
Yorkie in Drosophila, YAP causes aberrant tissue expansion in mice
and induces epithelial transformation in mammary cells [25,26].
Given the conservation of components and mechanisms that op-
erate downstream of merlin between Drosophila and mammals, we
tested the functional relationship among merlin, Hippo pathway reg-
ulation, and growth suppression in human meningioma tumors. We
developed nonneoplastic and neoplastic meningeal cell lines that
mimic gain or loss of NF2 expression and used these matched lines
to examine merlin regulation of YAP. We found that absence of
merlin results in loss of contact-dependent inhibition of growth
and promotes anchorage-independent growth. Merlin loss enhances
cell proliferation by increasing entry into the S-phase and cyclin E1
expression. Inactivation of merlin results in increased YAP expression
and nuclear accumulation of YAP in these meningioma cell lines and
in primary human meningioma tumors. Finally, we show that YAP
suppression reverses the proliferation effects associated with merlin
loss in meningiomas. Collectively, these data demonstrate that merlin
regulates cell growth in a YAP-dependent manner in meningiomas
and suggests that YAP is a compelling target for therapeutic inhibi-
tion of human meningioma tumor growth.
Materials and Methods
Tumor Samples, Cell Lines, and Culture
All human meningioma tumor samples were collected by the
Neurological Surgery Tissue Bank using protocols approved by the
University of California, San Francisco Committee on Human Re-
search. Human meningioma cell lines used were KT21MG1 [27]
and MENII-1. MENII-1 cells were isolated from a surgically resected
grade II meningioma and were immortalized by the expression of
telomerase and the human papillomavirus E6/E7 genes as described
earlier [28]. Human arachnoidal cells (AC1) were cultured by plat-
ing small fragments of surgically resected spinal arachnoid tissue
on scores scratched on the bottom of six-well tissue culture plates.
Within 7 days, cells with characteristic arachnoidal morphology
growing as a monolayer of polygonal cells with large cytoplasmic
arcs migrate out of these scores. The arachnoidal origins of these
cells were verified by positive staining for vimentin and desmoplakin.
Primary cultures of arachnoidal cells were immortalized by stable
transfection with the human papillomavirus E6/E7 oncogenes and
telomerase as described earlier [28]. All cell lines were maintained
in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum and appropriate antibiotic selection markers.
Expression Constructs and Antibodies
The pSUPER.retro.neo-NF2-siRNA construct was generated by
digesting the pSUPER.retro.neo vector (Oligoengine) with BglII
and Hind III and ligating the annealed oligos (5′-gatccccGCAG-
CAAGCACAATACCATttcaagagaATGGTATTGTGCTTGCTGC-
ttttta and 5′-agcttaaaaaGCAGCAAGCACAATACCATtctctt-
gaaATGGTATTGTGCTTGCTGCggg) that contain a 19-nucleo-
tide NF2 target sequence (in caps) using the strategy described
earlier [29]. The pSUPER.retro.neo-YAP-siRNA construct was also
generated in pSUPER.retro.neo using the strategy described above
and a previously described YAP target sequence (CCAGAGAATCA-
GTCAGAGA) [30]. A nonspecific mammalian scramble sequence
(Oligoengine, Seattle, WA) in pSUPER.retro.neo (pSUPER.retro.
neo-Control) was used as a control for the development of stable
cell lines. Wild type NF2, S518A NF2, and S518D NF2 mutant
constructs in pUHD10.3 have been previously described [7,31].
These three constructs were subcloned into pBABE-Hygro using
standard techniques. Merlin polyclonal (A19, #sc-331) and monoclo-
nal (B12, #sc-55575) antibodies and the cyclin E1 monoclonal
antibody (13A3, #sc-56310) were from Santa Cruz Biotechnology,
Santa Cruz, CA. The YAP monoclonal antibody (#4912) was from
Cell Signaling (Danvers, MA), the cyclin D1 monoclonal antibody
Figure 1. Schematic of the mammalian Hippo signaling pathway.
The Hippo pathway is an evolutionary conserved cellular pathway
that coordinately regulates cell proliferation and apoptosis. Merlin
has been proposed to interact with unknown membrane proteins
and transduce a signal that stimulates the phosphorylation of
LATS1/2 by the serine/threonine kinases MST1/2 that interact with
hWW45. LATS1/2 inhibits the transcriptional coactivator YAP re-
sulting in suppressed expression of downstream target genes
such as cyclins that are involved in cell growth and proliferation.
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(clone DCS-6) was from BD Pharmingen (Franklin Lakes, NJ),
and the α-tubulin (#CP06) antibody was from Calbiochem (San
Diego, CA).
Retroviral Infection and Selection of Stable Cell Populations
To stably suppress NF2 in MENII-1 and AC1 cell lines, retroviral
supernatants were generated by transfecting Phoenix A packag-
ing cells with pSUPER.retro.neo-NF2-siRNA or pSUPER.retro.
neo-Control using Lipofectamine 2000 Plus Reagent (Invitrogen,
Carlsbad, CA). The 48-hour posttransfection supernatant was har-
vested, filtered, and used to infect MENII-1 and AC1 cell lines in
the presence of 8 μg/ml polybrene. Stable cell populations were se-
lected using 500 μg/ml G418. In parallel, stable cell populations ex-
pressing wild type or mutant NF2 were generated by transfecting
Phoenix A cells with the particular pBABE-Hygro construct and in-
fecting KT21MG1 cells with the 48-hour posttransfection supernatant.
Stable cell populations were selected using 200 μg/ml hygromycin.
Empty pBABE-Hygro vector was used as a negative control.
Transient Suppression of YAP
Merlin-positive and -negative MENII-1 stable cell populations
generated above were plated at 80% confluency in 100-mm dishes
and transfected with 10 μg of pSUPER.retro.neo-YAP siRNA using
Lipofectamine 2000 Plus Reagent (Invitrogen). Empty pSUPER.
retro.neo vector was used as a negative control. The 72-hour post-
transfection cells were subjected to flow cytometry to quantify bro-
modeoxyuridine (BrdU) uptake (described below).
Quantitative Polymerase Chain Reaction
Quantitative polymerase chain reaction (PCR) was performed in
three independent experiments using cDNA templates with the I-
cycler machine (Bio-Rad, Hercules, CA) and SYBR Green I (Molec-
ular Probes, Eugene, OR) using PCR conditions and data analysis as
described earlier [32]. Primers specific for GAPDH and actin were
used to verify the integrity of the cDNA and to normalize cDNA
yields. The primers used were: GAPDH, 5′-GGAAGCTTGTCA-
TCAATGGAA and 5′-AAATGAGCCCCAGCCTTCTC; Actin,
5 ′ -CAGGAGGAGCAATGATCTTG and 5 ′ -ACTCTTC-
CAGCCTTCCTTCC; NF2, 5′-ACCGTTGCCTCCTGACATAC
and 5′-TCGGAGTTCTCATTGTGCAG; YAP, 5′-GCAGTTGG-
GAGCTGTTTCTC and 5′-GCCATGTTGTTGTCTGATCG;
cyclin E1, 5′-CCATCCTTCTCCACCAAAGA and 5′-TTTGA-
TGCCATCCACAGAAA; cyclin D1, 5′-TGTTTGCAAGCAG-
GACTTTG and 5′-CCTTCCGGTGTGAAACATCT.
Western Blot Analysis
Total cell lysates were prepared either in buffer A (50 mM Tris-
HCl, pH 7.5; 1 mM EDTA pH 8.0, 1% Triton) for merlin detec-
tion or in 1× SDS buffer following manufacturer’s instructions (Cell
Figure 2. In vitro model system of merlin expression in human meningeal cells. Endogenous merlin was silenced in AC1 and MENII-1
cells using NF2 specific siRNA. In parallel, merlin isoform 1 was exogenously expressed in KT21MG1 cells using retroviral mediated
gene transfer. (A) NF2 transcript levels were measured by quantitative PCR and showed a 5.6-fold reduction in MENII-1-NF2-siRNA cells
compared with MENII-1-Control cells. Asterisk denotes statistical significance (P < .05). (B) Western blot analysis of cell lysates derived
from AC1, MENII-1, and KT21MG1 stable cell populations was used to confirm loss or gain of merlin. Whereas merlin expression was ob-
served in AC1-Control and MENII-1-Control cells, NF2 siRNA abolished expression of merlin in AC1-NF2-siRNA and MENII-1-NF2-siRNA
cells. In parallel, KT21MG1-Control cells lacked merlin, whereas KT21MG1-NF2 cells expressed wild type merlin. Levels of α-tubulin were
determined in the same samples as a loading control. Immunoblot of one representative experiment of three with similar results is
shown. (C) Immunofluorescence using the A19 polyclonal antibody against merlin revealed the presence of cytoplasmic staining in
AC1-Control and MENII-1-Control cells and its absence in AC1-NF2-siRNA and MENII-1-NF2-siRNA cells. In contrast, KT21MG1-Control
cells had no staining, whereas KT21MG1-NF2 cells had cytoplasmic staining. Merlin immunolabeling is shown in green, and nuclear
DAPI counterstaining is shown in blue.
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Signaling) for YAP and cyclin protein detection. Protein (50-200 μg)
was resolved by electrophoresis for each sample and was transferred
to a polyvinylidenefluoride membrane. Membranes were blocked in
5% low-fat dry milk in Tris-buffered saline–Tween 20 and incubated
overnight at 4°C with either merlin A19 or B12 antibodies, or the
YAP, cyclin E1, or cyclin D1 antibody, or α-tubulin. Incubation with
horseradish peroxidase–conjugated goat antirabbit or antimouse im-
munoglobulin (Jackson Immunoresearch, West Grove, PA) was per-
formed for 1 hour at room temperature. Bound antibody was
visualized by chemiluminescence using the SuperSignal West Pico
substrate (Pierce Chemical Co., Rockford, IL). The molecular
weights were determined with the use of prestained protein ladders
(BioRad, Hercules, CA, and Invitrogen). Films were scanned and ex-
ported as TIFF files.
Immunofluorescence Microscopy
Indirect immunofluorescence for merlin (A19 antibody or B12 an-
tibody) and YAP was performed as described earlier [28]. Briefly, cells
were fixed, permeabilized, blocked, and sequentially incubated with
primary and secondary (Alexa 488 goat antirabbit IgG or Alexa 546
goat antimouse IgG) antibodies. Cells were mounted in DAPImount-
ing media, examined, and photographed with a microscope (Zeiss,
Thornwood, NY).
Immunohistochemistry
Immunohistochemical staining was performed on 5-μm formalin-
fixed, paraffin-embedded sections from meningioma tissue (8 pri-
mary tumors) and from a meningioma tissue microarray (29 primary
tumors) for merlin (B12 antibody) and YAP as described earlier [33].
Slides were reviewed in consultation with a neuropathologist (S.R.V.)
and included 33 WHO grade I and 4 WHO grade III meningiomas.
Growth Curves and Soft Agar Assay
Merlin-positive and -negative stable cell populations (20,000 cells)
were plated in 24-well plates, and cells from three wells were counted
at 3, 6, 12, 18, 25, and 30 days. To assess colony growth in soft agar,
50,000 cells were plated in Dulbecco’s modified Eagle’s medium in
0.4% low melting temperature agarose upon a layer of 0.8% agarose.
After 8 weeks, colonies were stained with 0.005% crystal violet, and
colonies larger than 100 μm in diameter were scored by counting
under a microscope.
Flow Cytometry
Cells (70-80% confluent) were incubated with 1 mM BrdU for
3 hours at 37°C and processed using the fluorescein isothiocyanate
BrdU Flow Kit (BD Biosciences, San Jose, CA) following manufac-
turer’s instructions. Briefly, 1 × 106 trypsinized cells were fixed,
permeabilized, and digested with DNAse. Cells were then stained
with fluorescein isothiocyanate–conjugated anti-BrdU and 7-amino-
actinomycin (7-AAD). Flow cytometry was performed on a Becton
Dickinson FACSCalibur machine. For each experiment, 10,000
events were counted. Data acquisition was performed with the Cell-
Quest software (BD Biosciences), and data were analyzed using Flow
Jo v8.5.3.
Statistics
All data are expressed as mean ± SEM. GraphPad Prism version 4
was used for statistical analysis, consisting of unpaired t test and sig-
nificant differences with a P < .05.
Results
Establishment of Matched NF2-Expressing and NF2-Deficient
Human Arachnoidal and Meningioma Cell Lines
To develop a meningioma-specific NF2 in vitro model system,
we determined the expression levels of endogenous merlin in normal
human arachnoidal and meningioma cell lines (data not shown). On
the basis of these results, we selected one arachnoidal cell line (AC1),
one merlin-positive grade II meningioma cell line (MENII-1), and
one merlin-negative grade III meningioma cell line (KT21MG1)
for further analysis. Paired cell lines were generated by either sup-
pressing NF2 expression in AC1 and MENII-1 cells using RNA in-
terference (siRNA) or by overexpressing the full-length human NF2
cDNA (isoform 1, lacking exon 16 sequences) in KT21MG1 cells after
retroviral-mediated gene transfer. Stable cell populations expressing
either NF2 siRNA (AC1-NF2-siRNA or MENII-1-NF2-siRNA) or
a nonspecific target siRNA (AC1-Control or MENII-1-Control) were
Figure 3. Suppression of merlin causes loss of contact-dependent
inhibition of growth and promotes anchorage-independent
growth. (A) Growth curves in the presence and absence of merlin
expression. Cultures were subconfluent during the first 6 days.
MENII-1-NF2-siRNA cells (dotted lines) continued growing after
confluent conditions and have less contact-dependent inhibition
of growth compared with MENII-1-Control cells (solid lines). Each
line corresponds to representative cultures. (B) NF2 suppression
promotes anchorage-independent growth. Marked increased in
colony formation in soft agar was observed in cells without merlin
expression as MENII-1-NF2-siRNA and KT21MG1-Control cells
compared with MENII-1-Control and KT21MG1-NF2, respectively.
Representative images of the colonies formed (upper panel) and
the mean number of colonies per well (lower panel) are shown.
Error bars equal ±SE of three independent experiments. Asterisks
denote statistical significance (P < .05).
Neoplasia Vol. 10, No. 11, 2008 Merlin Signals Through YAP in Meningiomas Striedinger et al. 1207
selected. NF2 transcript levels were 5.6-fold lower in MENII-1-NF2-
siRNA cells when compared with MENII-1-Control cells using quan-
titative PCR (Figure 2A). Similarly, merlin protein expression was
undetectable in AC1-NF2-siRNA and MENII-1-NF2-siRNA cells
by Western blot analysis and immunofluorescence (Figure 2, B and
C ). In parallel, stable cell populations expressing either exogenous
merlin (KT21MG1-NF2) or empty vector (KT21MG1-Control)
were selected. Expression of merlin in KT21MG1-NF2 cells was con-
firmed byWestern blot and immunofluorescence (Figure 2, B and C ).
In total, we have generated three separate human meningeal and me-
ningioma cell lines that differ only in their expression of merlin for
subsequent study.
Merlin Loss Increases S-Phase Entry, Cell Proliferation, and
Promotes Anchorage-Independent Growth
Next, we assessed the effect of merlin loss on the growth proper-
ties of these human meningioma cell lines. MENII-1-NF2-siRNA
cells exhibited a more pronounced loss of contact-dependent inhibi-
tion of growth compared with MENII-1-Control cells (Figure 3A).
Merlin loss also promoted colony formation in soft agar. In these
experiments, MENII-1-NF2-siRNA cells formed a greater number
of colonies (10.6 ± 3.2) larger than 100 μm in diameter compared
with MENII-1-Control cells (0.4 ± 0.4; P = .01; Figure 3B). Con-
versely, merlin expression in KT21MG1 cells significantly decreased
the formation of colonies (32 ± 6.3) compared with merlin-negative
KT21MG1 cells (361 ± 4.9; P ≤ .0001; Figure 3B).
To determine the effect of merlin on cell cycle progression, we
measured BrdU incorporation and total DNA content by flow cy-
tometry. Loss of merlin in AC1 and MENII-1 cells resulted in a
significant increase in the percentage of BrdU-positive cells, indicated
by an increase in S-phase entry (Figure 4). This is consistent with the
observed increase in proliferation in NF2-deficient cells. Conversely,
expression of exogenous merlin in KT21MG1 cells induced G0/G1
arrest and a concomitant decrease in the S-phase cell population (Fig-
ure 4). These results demonstrate that merlin functions as a negative
growth regulator for both nonneoplastic leptomeningeal cells and
meningioma cells and establishes this system as a tractable experi-
mental platform for examining growth regulatory pathways.
Merlin Loss Is Associated with an Increase in
YAP Protein Expression
In Drosophila, merlin controls cell proliferation and apoptosis by
signaling through the Hippo pathway and its effector protein Yorkie,
the ortholog of YAP [16,18]. To determine whether merlin might
regulate meningioma cell growth by modulating Hippo pathway sig-
naling, we investigated whether changes in merlin expression were
associated with altered levels of YAP using our human NF2 meningi-
oma model system. Transcript levels of YAP were unaffected by merlin
loss in MENII-1 cells (data not shown); however, YAP protein ex-
pression was elevated in arachnoidal and meningioma cells lacking
merlin expression and decreased in KT21MG1 cells expressing wild
type merlin (Figure 5A). These results suggest that merlin regulates
YAP expression at the translational or posttranslational level.
Figure 4.Merlin loss enhances S-phase entry. AC1 andmeningioma cell lines (MENII-1 and KT21MG1) were labeled with BrdU and 7-AAD
to assess the cell cycle distribution of individual cells by flow cytometry. (A) Representative flow cytometric histograms indicate an in-
crease in the percent of BrdU-positive cells in AC1-NF2-siRNA, MENII-1-NF2-siRNA, and KT21MG1-Control cells compared with AC1-
Control, MENII-1-Control, and KT21MG1-NF2 cells, respectively. (B) Bar graphs depict the percentage of cells in the S-phase of the cell
cycle (BrdU-positive cells) averaged from three independent experiments. Error bars correspond to ±SE. Asterisks denote statistical sig-
nificance using unpaired t test (P< .05). (C) Table shows themean of the percentage of cells ±SE in each phase of the cell cycle from three
independent experiments.
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Merlin becomes active after dephosphorylation of the conserved
C-terminal serine 518 (S518) residue [31,34]. Previous studies have
shown that merlin mutants in which this phosphorylatable residue
is changed to alanine (S518A) are constitutively nonphosphorylated
and active, whereas those containing aspartic acid (S518D) are
pseudophosphorylated and nonfunctional as negative growth reg-
ulators [31,34]. Using these mutants, we assessed the effect of
merlin phosphorylation status on YAP protein levels in KT21MG1
human meningioma cells. YAP protein levels were markedly up-
regulated in KT21MG1 cells expressing the S518D inactive mutant
compared with those with active merlin S518A expression (Fig-
ure 5A), suggesting that active and functional merlin was required
to inhibit YAP.
YAP has been reported to shuttle between the cytoplasm and
the nucleus where it can function as a transcriptional coactivator
[35]. To determine whether merlin regulates the subcellular localiza-
tion of YAP, we used fluorescence immunocytochemistry to examine
NF2-deficient and NF2-expressing AC1 and MENII-1 cells. YAP
was preferentially expressed in the cytoplasm of AC1-Control and
MENII-1-Control cells. In contrast, YAP was localized in the nu-
cleus in AC1-NF2-siRNA and MENII-1-NF2-siRNA cells (Fig-
ure 5B). Collectively, these data indicate that merlin regulates YAP
protein expression and YAP nuclear localization.
To assess whether a similar association exists between merlin and
YAP in human meningioma tumors, we surveyed 37 sporadic primary
meningioma tumors by immunohistochemistry. After immunostain-
ing with a merlin-specific monoclonal antibody, meningiomas were
classified as either merlin-positive, if tumors exhibited any positive
immunoreactivity, or merlin-negative, if tumors had no immunore-
activity. We then assessed protein levels of YAP in adjacent serial
sections. 13 (92%) of 14 merlin-negative meningiomas exhibited
strong nuclear YAP immunoreactivity. In contrast, 22 (95%) of
23 merlin-positive meningiomas had weak to no YAP immunore-
activity (Figure 5C ). These results further support the in vitro re-
sults demonstrating that merlin regulates YAP protein levels in vivo.
Merlin Loss Is Associated with an Increase in Protein Levels of
Cyclin E1
Previous studies have identified cyclin E1 as a transcriptional target
of the Hippo pathway in Drosophila [36–38] and an essential reg-
ulator of progression from G1 to S cell cycle progression in mam-
malian cells [39,40]. Also, merlin has been reported to inhibit cell
proliferation by repressing cyclin D1 in human mesothelioma cells
[41]. To determine whether merlin regulates cyclin E1 and/or cy-
clin D1 levels in human meningioma cells, we measured cyclin E1
and D1 RNA and protein expression by quantitative PCR and
Western blot analysis, respectively. Cyclin E1 transcript levels were
at least 2.5-fold higher in MENII-1-NF2-siRNA cells compared
with MENII-1-Control cells, whereas cyclin D1 transcript levels
were the same in MENII-1-NF2-siRNA and MENII-1-Control
cells (Figure 6A). In addition, cyclin E1 protein levels were ele-
vated in MENII-1-NF2-siRNA and AC1-NF2-siRNA cells com-
pared with MENII-1-Control and AC1-Control cells, respectively
(Figure 6B). Conversely, exogenous expression of merlin in NF2-
deficient KT21MG1 cells resulted in decreased cyclin E1 protein
levels. In contrast, cyclin D1 protein levels were unaffected by the
absence or presence of merlin in both MENII-1 and KT21MG1
cells (Figure 6C ). These data suggest that merlin likely regulates cell
Figure 5. Protein levels of YAP are up-regulated and localized to
the nucleus in NF2-deficient cells. (A) Total cell lysates were sub-
jected to Western blot using a YAP- or merlin-specific antibody.
Increased YAP protein expression was observed when NF2 was
suppressed in AC1 and MENII-1 cells compared with controls.
Conversely, exogenous expression of merlin decreased YAP in
KT21MG1 cells compared with controls. Expression of a nonphos-
phorylated, active merlin (S518A NF2) was also associated with
lower levels of YAP compared with the expression of pseudophos-
phorylated inactivemerlin (S518DNF2). Levels of α-tubulin were de-
termined in the same samples as loading control. Results were
reproduced in three independent experiments. (B) YAPwas translo-
cated to the nucleus in merlin-deficient cells. Immunofluorescence
staining was used to show that YAP was localized to the nucleus in
AC1-NF2-siRNA, MENII-1-NF2-siRNA, and KT21MG1-Control cells.
In contrast, YAPwas primarily cytoplasmic in AC1-Control, MENII-1-
Control, and KT21MG1-NF2 cells. Merlin immunolabeling is shown
in red; YAP staining is shown in green; and nuclear DAPI counter-
staining is shown in blue. (C) In situ immunostaining of merlin and
YAP in serial sections of primary human meningioma tumors. We
surveyed 37 primary meningiomas by immunohistochemistry. YAP
expression was minimal to absent in 95% of merlin-positive menin-
giomas (a representative tumor is shown here asMeningioma 1). In
contrast, YAPwas expressed and localized to the nucleus in 92%of
merlin-negative meningiomas (a representative tumor is shown
here as Meningioma 2). Arrow depicts an example of YAP nuclear
localization. Insets show images at higher magnification.
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growth by modulating cyclin E1 expression at the transcriptional level
in meningiomas.
YAP Reduction Reverses the Growth Phenotype Associated with
Merlin Loss
Lastly, to determine whether YAP expression is necessary for the
enhanced S-phase entry induced by merlin loss in meningioma cells,
we transiently depleted YAP using RNA interference in MENII-1-
Control and MENII-1-NF2-siRNA cells (Figure 7). Reduced YAP
expression in NF2-deficient MENII-1 meningioma cells caused a
∼50% decrease in the percentage of cells in S-phase (9 ± 1.2) com-
pared with mock-transfected cells (20 ± 0.2; P = .001; Figure 7, B
and C ). In contrast, YAP siRNA treatment had a minor effect on
MENII-1-Control cells (∼20% reduction; P = .08; Figure 7, B and
C ). Collectively, these experiments demonstrate that YAP transduces
the merlin growth regulatory signal in meningiomas and that the
Hippo growth control pathway is responsible for merlin tumor sup-
pressor function in this tumor type.
Discussion
The Hippo signaling pathway is emerging as an evolutionarily
conserved mechanism that controls organ size and growth relevant
to tumorigenesis [18,37]. In this study, we investigated the functional
association between NF2 gene expression and the downstream ef-
fector of the Hippo pathway in human meningiomas. We provide
several lines of converging and complementary evidence that merlin
functions through YAP in meningiomas. First, using paired menin-
gioma cell lines differing only in NF2 expression, we show that
YAP expression is increased in a dose-response manner upon merlin
loss. This regulation occurs at the translational or posttranslational
level and results in YAP nuclear localization. Second, the relation-
ship between merlin expression and YAP nuclear localization is also
observed in human surgical meningioma specimens in vivo. These
observations are consistent with findings made in other solid can-
cers in which Hippo signaling is deregulated [42]. Third, sup-
pressed YAP expression in merlin-deficient meningioma cells
attenuates the cell growth and S-phase cell cycle progression asso-
ciated with merlin loss. To the best of our knowledge, these results
represent the first demonstration that merlin regulates cell growth
in human meningioma cells by suppressing YAP, the main Hippo
pathway effector protein.
YAP has previously been implicated in other human cancers, in-
cluding pancreatic ductal adenocarcinoma, and has been shown to
function as an oncogene that induces epithelial transformation of
mouse mammary cells [26,43]. Nuclear localization of YAP is depen-
dent on the phosphorylation status of a conserved Ser residue and is
necessary for its cotranscriptional activator function [35,44]. YAP as-
sociates with multiple transcription factors in the nucleus such as p73
and TEAD/TEF [44,45]. ErbB4 receptors have been reported to re-
cruit YAP and relocate to the nucleus to regulate transcription
[46,47]. In contrast, LATS1 inactivates YAP oncogenic function by
sequestering YAP in the cytoplasm and, consequently, suppressing its
transcriptional regulation of cellular genes [35]. Our findings are in
accordance with these and suggest that the tumorigenic behavior of
meningioma cells is driven in part by YAP nuclear localization and
the transcription of genes involved in increased proliferation.
Figure 6. Cyclin E1 and cyclin D1 expression was increased in merlin-deficient cells. (A) Transcript levels of cyclin E1 and cyclin D1 were
measured in MENII-1 cells using quantitative PCR. At least a 2.5-fold increase in the transcript levels of cyclin E1 was seen in MENII-1-
NF2-siRNA cells compared with MENII-1-Control cells, whereas transcript levels of cyclin D1 were unchanged. Asterisk denotes statis-
tical significance (P < .05). (B) Western blot analysis of cell lysates derived from AC1, MENII-1, and KT21MG1 stable cells was used to
show that protein levels of cyclin E1 were increased in the absence of merlin. Levels of α-tubulin were determined in the same samples
as a loading control. (C) Western blot analysis of cell lysates derived from MENII-1 and KT21MG1 stable cells was used to show that
protein levels of cyclin D1 were unchanged in the absence of merlin. Levels of α-tubulin were determined in the same samples as a
loading control.
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We demonstrate that merlin controls the cell cycle in meningiomas.
Merlin suppression results in increased S-phase entry, and merlin
expression resulted in G0/G1 arrest. Similar results were obtained
in mesotheliomas [41] and schwannomas [48]. These results pro-
vide strong evidence that merlin functions as a tumor suppressor
by controlling the G0/G1– to S-phase checkpoint of the cell cycle.
Cyclin E1 is thought to be essential for this cell cycle transition in
humans [39,40] and has been identified as a downstream target of
Yorkie in Drosophila [36–38]. In contrast, cyclin E1 was not in-
duced after overexpression of YAP in mammary epithelial cells
[26]. Instead, it has been shown that cyclin D1 is regulated by
YAP in mouse intestine [25] and by merlin in human mesothelio-
mas [41]. Our experiments show that merlin regulates cyclin E1
but not cyclin D1 in human meningiomas. These differences most
likely represent cell type–specific differences in gene expression.
Further studies are needed to determine whether merlin regulates cy-
clin E1 by signaling through YAP.
The fact that NF2 patients develop only certain CNS tumors also
emphasizes the cell type–specific tumorigenic effects of merlin.
Merlin loss results specifically in aberrant growth of Schwann and
meningeal cell types. However, not all meningiomas have NF2 loss,
suggesting that other mechanisms that do not involve the Hippo
pathway result in meningioma formation. Alternatively, it remains
to be elucidated whether other components of the Hippo pathway,
downstream of merlin, are possibly deregulated in these tumors re-
sulting in the same phenotype as merlin loss.
Treatment strategies for NF2 and sporadic meningioma patients
are restricted to traditional forms of cancer therapy such as surgery
and radiation therapy. These options are sometimes insufficient be-
cause of the location of these tumors, the recurrence despite therapies
and the occurrence of multiple tumors. Although receptor tyrosine
kinases inhibitors are emerging as pathway targets in other CNS tu-
mors such as glioblastomas [49], targeted therapies have not yet been
proposed for meningioma patients. This is mainly because of a lack
of knowledge regarding relevant signaling pathways. Our results
argue that YAP is an attractive candidate as a key mediator of NF2
growth regulation and tumorigenesis in meningioma, making it a po-
tential target for the development of therapies for NF2 and menin-
gioma patients.
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